Insiders Trades
DENTSPLY SIRONA Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 16 Jun 2026.
DENTSPLY SIRONA Inc.: what insiders have been doing
DENTSPLY SIRONA Inc., founded in 1899, is a Healthcare & Pharma company based in York, United States. Its directors and officers file their transactions with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 54 filings came from 18 insiders.
The record shows 10 purchases on the open market worth €694k, made by 8 insiders, against 1 sale worth €787k by 1 insider. The amount is not disclosed for 5 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Those buying include 8 senior executives. At €787k, the sale published on 10 December 2025 by Lucier Gregory T is the largest of the period.
Compared with its exchange (5,816 companies, median 19 filings), a count of 54 filings is above the norm. Looking back to 2021, when coverage begins, insiders filed 21 purchases and 5 sales. The 10-K for the year ended 31 December 2025 shows 3.68 bn USD of revenue and -598.0 m USD of net income and a dividend of 0.64 USD per share.
Within a 30-day window, 4 purchases overlapped with buying by a second insider. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The clock since the last published purchase (16 June 2026) now reads 123 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
520
Thresholds
n/a
Buy Volume
€3M
21 ops. · all time
Sell Volume
€3M
5 ops. · all time
Who traded when
BuySaleGregory T. Lucier5 buys1 sale
James D. Forbes2 buys
Betsy D. Holden1 buy
Brian P. Mckeon1 buy
Brian T. Gladden1 buy
Clyde Hosein1 buy
+3 other insiders
Since the insiders bought
- -14.3%Entry US$10.03 · Close 16 Oct 2026 US$8.60
- -17.8%Entry US$10.45 · Close 16 Oct 2026 US$8.60
- -17.8%Entry US$10.45 · Close 16 Oct 2026 US$8.60
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate DENTSPLY SIRONA Inc. Hold (neutral), based on 15 analysts. Average price target: US$13.27.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,226 of 24,148 companies
34.3
score / 100
Value39
Quality30
FCF yld6.1%
Earn yld-35%
EV/EBITDA·
ROE-33%
Gross mgn50%
Net mgn-16%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$8.51
Analyst consensus
15 analystsHold
US$9.00Target US$13.27(+56%)US$17.00
Income statement
RevenueUS$3.7B
Gross profitUS$1.8B50% margin
EBITDA-US$46M-1% margin
Net income-US$598M-15.0% margin
Valuation
PER (forward)5.7x
P/Book1.3x
Beta0.88
Balance sheet & cash
Market capUS$1.7B
Total debtUS$2.5B
Free Cash FlowUS$104M
Debt / Equity172%
Profitability & ownership
ROE-33.0%
ROA2.0%
% insiders0.6%
% institutions117.4%
Last declaration on 12 August 2026
Declarations520 total
24,014 shares0Common StockSEC:0000818479-26-000268:0
802 shares@ US$12.120.0005% mcap12.3% of flowCommon StockSEC:0000818479-26-000266:0
6,500 sharesCommon StockSEC:0000818479-26-000214:0
Canonical exit: 13 Sept 2026 (T+90)
10,000 sharesCommon StockSEC:0000818479-26-000212:0
Canonical exit: 10 Sept 2026 (T+90)
15,175 sharesCommon StockSEC:0000818479-26-000208:0
Canonical exit: 9 Sept 2026 (T+90)
10,086 sharesCommon StockSEC:0000818479-26-000209:0
Canonical exit: 9 Sept 2026 (T+90)
10,000 sharesCommon StockSEC:0000818479-26-000210:0
9,985.022 sharesCommon StockSEC:0000818479-26-000211:0
Canonical exit: 13 Sept 2026 (T+90)
28,887 shares0Common StockSEC:0000818479-26-000184:0
22,822 shares0Common StockSEC:0000818479-26-000185:0
22,822 shares0Common StockSEC:0000818479-26-000183:0
22,822 shares0Common StockSEC:0000818479-26-000186:0
22,822 shares0Common StockSEC:0000818479-26-000187:0
22,822 shares0Common StockSEC:0000818479-26-000188:0
28,887 shares0Common StockSEC:0000818479-26-000189:0
22,822 shares0Common StockSEC:0000818479-26-000190:0
22,822 shares0Common StockSEC:0000818479-26-000191:0
22,822 shares0Common StockSEC:0000818479-26-000192:0
38,382 shares0Common StockSEC:0000818479-26-000193:0
38,382 shares0Common StockSEC:0000818479-26-000193:1
38,382 shares0Common StockSEC:0000818479-26-000193:2
15,000 shares@ US$12.4456.8% of flowCommon StockSEC:0000818479-26-000107:0
Canonical exit: 7 Jun 2026 (T+90)
5,000 shares@ US$12.4848.5% of flowCommon StockSEC:0000818479-26-000106:0
Canonical exit: 7 Jun 2026 (T+90)
13,690 shares0Common StockSEC:0000818479-26-000104:0
59,524 shares0Common StockSEC:0000818479-26-000102:0
25 of 520 declarations
About DENTSPLY SIRONA Inc.
DENTSPLY SIRONA Inc. (ticker: XRAY) is a U.S.-listed dental technology and consumables company traded on the Nasdaq in the United States. For investors, it sits at the intersection of healthcare, medical devices, and dental workflow technology, with exposure to recurring consumables as well as more capital-intensive equipment and digital imaging systems. The company’s global headquarters is in Charlotte, North Carolina, a relevant detail for European investors following U.S. healthcare names. ([investor.dentsplysirona.com](https://investor.dentsplysirona.com/news-releases/news-release-details/dentsply-sirona-reports-fourth-quarter-and-full-year-2024/?utm_source=openai))
The company’s heritage reflects the combination of two established dental businesses: DENTSPLY, whose roots go back to the late 19th century, and Sirona, a German dental equipment and imaging specialist. Their merger created a broader platform spanning the consumables, equipment, and software layers of the dental ecosystem. Dentsply Sirona emphasizes its international footprint, distributing products in more than 150 countries, which gives it wide market reach but also exposes it to foreign exchange, regional demand cycles, and competitive intensity. ([fintel.io](https://fintel.io/doc/sec-dentsply-sirona-inc-818479-10k-2024-february-29-19782-244?utm_source=openai))
Read moreShow less
Operationally, the group offers a diversified portfolio across restorative dentistry, endodontics, implants and prosthetics, orthodontics, imaging and diagnostics, dental chairside equipment, and connected digital workflow solutions. Its competitive position is built on breadth of product range, long-standing brand recognition, installed base relationships, and the ability to bundle hardware, consumables, and software into integrated clinical workflows. Strategically, that matters because dentistry is increasingly shaped by digital tools, 3D imaging, and efficiency-focused practice management. ([investor.dentsplysirona.com](https://investor.dentsplysirona.com/static-files/0d4ca110-18df-4dcc-85d4-ca53822531c8?utm_source=openai))
Dentsply Sirona remains a global business with a meaningful presence in North America, Europe, and other international markets. In 2024, the company employed approximately 4,600 people and continued to optimize its geographic footprint to improve efficiency. For investors, that suggests a mature operating base with global diversification, but also a need for disciplined execution in a slower-growth end market. ([investor.dentsplysirona.com](https://investor.dentsplysirona.com/static-files/0d4ca110-18df-4dcc-85d4-ca53822531c8?utm_source=openai))
Recent developments have been important. Fiscal 2024 included material non-cash impairment charges tied to orthodontics, implants, and connected technology, reflecting weaker demand and competitive pressure in some categories. In 2025 and 2026, the company went through notable leadership changes: Dan Scavilla was appointed CEO, Matt Garth became CFO, and the business launched a “Return-to-Growth” action plan aimed at sharpening commercial execution, improving the customer experience, and optimizing capital allocation. In October 2025, Dentsply Sirona also disclosed that the SEC investigation opened in May 2022 had concluded and that the SEC did not intend to take enforcement action. ([investor.dentsplysirona.com](https://investor.dentsplysirona.com/news-releases/news-release-details/dentsply-sirona-reports-fourth-quarter-and-full-year-2024/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
